Carbenicillin plus cephalothin or cefazolin as therapy for infections in neutropenic patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000150:complications*; D002228:Carbenicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002437:Cefazolin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002512:Cephalothin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D006801:Humans; D007239:Infections / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications*; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced
D002511:Cephalosporins; D002228:Carbenicillin; D002437:Cefazolin; D002512:Cephalothin